Compounds > geranylgeranylacetone
Page last updated: 2024-08-01 11:33:11

geranylgeranylacetone

Description

geranylgeranylacetone: structure in first source; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers [MeSH]

Cross-References

ID SourceID
PubMed CID5282199
CHEMBL ID79686
SCHEMBL ID157511
SCHEMBL ID157509
CHEBI ID31649
MeSH IDM0097855

Synonyms (52)

Synonym
CHEMBL79686
unii-57b67oxm8f
5,9,13,17-nonadecatetraen-2-one, 6,10,14,18-tetramethyl-, (e,e,e)-
57b67oxm8f ,
e-671
selbelle
tetraprenylacetone
ea-0671
selbex
teprenona [inn-spanish]
teprenonum [inn-latin]
5,9,13,17-nonadecatetraen-2-one, 6,10,14,18-tetramethyl-
teprenone
geranylgeranylacetone
6809-52-5
geranylgeranyl acetone
6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
NCGC00182034-01
(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
3796-63-2
tox21_112960
dtxcid9028546
dtxsid6048620 ,
cas-6809-52-5
unii-s8s8451a4o
teprenonum
teprenona
teprenone [inn:jan]
s8s8451a4o ,
AKOS015894922
S5006 ,
SCHEMBL157511
SCHEMBL157509
CS-3560
HUCXKZBETONXFO-NJFMWZAGSA-N
(9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
CHEBI:31649 ,
5,9,13,17-nonadecatetraen-2-one, 6,10,14,18-tetramethyl-, (5e,9e,13e)-
(e,e,e)-geranylgeranyl acetone
Q-201789
HY-B0779
SR-01000944917-1
sr-01000944917
(5z,9z,13z)-geranylgeranylacetone
3879-24-1
(5z,9z,13e)-geranylgeranylacetone
BCP11723
Q7701388
CCG-267813
(5e,9e,13e)-6,10,14,18-tetramethyl-5,9,13,17-nonadecatetren-2-one
DTXSID901166719
(5e,9e,13e)-6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2-one

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.6852AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency30.9008AID1645841
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.2449AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency23.7101AID1346982
GVesicular stomatitis virusPotency17.3768AID1645842
aryl hydrocarbon receptorHomo sapiens (human)Potency33.4915AID743085
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.9744AID743065; AID743067
Interferon betaHomo sapiens (human)Potency17.3768AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.3768AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.3768AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.3768AID1645842

Bioassays (35)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID183872In Vivo gastric Mucosal protective activity against gastric mucosal lesions induced by 0.6 N HCl in rats. (200 mg/kg, po)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
ISSN: 0022-2623		Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID1657043Induction of HSP70 expression in rat PC12 cells at 10 uM incubated for 4 hrs by Western blot analysis2020Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7
ISSN: 1464-3405		HSP70 induction by bleomycin metal core analogs.

Research

Studies (307)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (8.47)18.7374
1990's46 (14.98)18.2507
2000's118 (38.44)29.6817
2010's92 (29.97)24.3611
2020's25 (8.14)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (7.89%)5.53%
Reviews18 (5.68%)6.00%
Case Studies1 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other273 (86.12%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
cimetidine
1
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1992199232.0low001000
ranitidine
1
aralkylamine1992199232.0low001000
ku 1257
1
piperidines1992199232.0low001000
famotidine
1
1,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1992199232.0low001000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetic acid
5
monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent		1985200730.8low030200
adenine
1
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2011201113.0low000010
ammonium hydroxide
3
azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant		1999200720.0low001200
hydrochloric acid
4
chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite1982200730.5low021100
lactic acid
1
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		201720177.0low000010
glycerol
1
alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent		1987198737.0low010000
hydrogen carbonate
4
carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1987200231.5low012100
histamine
2
aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter		2004200519.5low000200
hydrogen
1
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		1994199430.0low001000
nitrates
1
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		1998199826.0low001000
nitrites
2
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite1998200522.5low001100
palmitic acid
1
long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite		1987198737.0low010000
xanthine
1
xanthineSaccharomyces cerevisiae metabolite1991199133.0low001000
1-anilino-8-naphthalenesulfonate
1
aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe1995199529.0low001000
3-nitropropionic acid
1
C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin		2010201014.0low000100
5-hydroxydecanoate
2
medium-chain fatty acid2007201015.5low000200
acetaminophen
1
acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2006200618.0low000100
aspirin
7
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		1982201926.3low231120
celecoxib
1
organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		2006200618.0low000100
cetraxate
3
benzenes;
monocarboxylic acid		1988200726.7low011100
chelerythrine
2
benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		2003200619.5low000200
chloroquine
1
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		2011201113.0low000010
cimetidine
12
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1981200733.9low256100
diazoxide
1
benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent		2010201014.0low000100
diclofenac
5
amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2007202110.8low400221
donepezil
1
aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent		201920195.0low100010
famotidine
4
1,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1990201416.5low301030
gentamicin
4
200720199.0low000130
glyburide
2
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		1991200725.0low001100
indomethacin
7
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		1986201425.9low023110
isoflurane
1
organofluorine compoundinhalation anaesthetic2014201410.0low000010
staurosporine aglycone
1
201720177.0low000010
lansoprazole
2
benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		1998199826.0low102000
loxoprofen
1
cyclopentanones;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug		2011201113.0low000010
metformin
1
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		2011201113.0low000010
omeprazole
9
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		1987201223.7low415210
proglumide
2
benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate		anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite		1985198638.5low020000
rabeprazole
4
benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor		1999201417.2low201210
opc 12759
3
secondary carboxamide1998200722.7low102100
sevoflurane
1
ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor		2008200816.0low000100
sulpiride
1
benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist		2007200717.0low000100
tegafur
1
organohalogen compound;
pyrimidines		1991199133.0low001000
tranexamic acid
3
amino acid1988200726.7low011100
troxipide
1
benzamides2002200222.0low000100
mitomycin
1
mitomycinalkylating agent;
antineoplastic agent		1991199133.0low001000
prednisolone
2
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic		2005200817.5low000200
hydroxyproline
2
4-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite		2009201512.0low000110
prednisone
1
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug		2006200618.0low000100
carbon tetrachloride
3
chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant		1999201813.3low001020
alanine
3
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		1998200722.7low102100
carbostyril
3
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite1998200722.7low102100
edetic acid
1
ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector		1995199529.0low001000
methylene blue
1
organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer		2014201410.0low000010
methionine
1
aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2003200321.0low000100
cycloheximide
1
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		1996199628.0low001000
taurocholic acid
2
amino sulfonic acid;
bile acid taurine conjugate		human metabolite1987199831.5low011000
triethylene glycol dimethacrylate
1
201620168.0low000010
framycetin
1
aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite		201820186.0low000010
thiazoles
1
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2011201113.0low000010
triphenyltetrazolium
3
organic cation2005200618.7low000300
hydrazine
1
azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor1988198836.0low010000
kainic acid
2
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		2004201713.5low000110
methamphetamine
1
amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic		2013201311.0low000010
malondialdehyde
3
dialdehydebiomarker2012201510.7low000030
trinitrobenzenesulfonic acid
2
arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent		2006200717.5low000200
acetylcysteine
3
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		1993200227.3low002100
methylnitrosourea
1
N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent		201620168.0low000010
d-alpha tocopherol
1
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		2004200420.0low000100
chloramine
1
halide2006200618.0low000100
tetradecanoylphorbol acetate
1
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		2000200024.0low001000
phosphotyrosine
1
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen		201620168.0low000010
phenyl acetate
3
benzenes;
phenyl acetates		1985198738.0low030000
glutamic acid
1
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		202020204.0low000010
amoxicillin
2
penicillin allergen;
penicillin		antibacterial drug1998199826.0low102000
ribavirin
1
1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		2011201113.0low000010
1-methyl-4-phenylpyridinium
1
pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin		2002200222.0low000100
nitazoxanide
1
benzamides;
carboxylic ester		2011201113.0low000010
cefaclor anhydrous
1
cephalosporinantibacterial drug;
drug allergen		1991199133.0low001000
clopidogrel
1
methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		201920195.0low000010
adenosine
1
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		1991199133.0low001000
dansyl hydrazine
1
1988198836.0low010000
p-methoxy-n-methylphenethylamine
3
aromatic ether;
secondary amino compound		metabolite2003200520.0low000300
paxilline
1
diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker		2005200519.0low000100
mosapride
2
aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound		2012201212.0low200020
florox reagent
1
1982198242.0low010000
omega-n-methylarginine
2
amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		1998199925.5low002000
phytol
1
2005200519.0low000100
deoxycholic acid
1
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite1998199826.0low001000
wortmannin
3
acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent		201020189.0low000120
pifithrin mu
1
benzenes2014201410.0low000010
glucosamine
1
D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite		2000200024.0low001000
carnosine
1
amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent		2002200222.0low000100
cholesteryl glucoside
1
monosaccharide derivative;
sterol 3-beta-D-glucoside		2003200321.0low000100
tretinoin
1
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		1993199331.0low001000
resveratrol
1
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		2005200519.0low000100
oleic acid
1
octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent		1987198737.0low010000
geranylgeranyl pyrophosphate
1
geranylgeranyl diphosphatemouse metabolite2004200420.0low000100
dactinomycin
1
actinomycinmutagen1996199628.0low001000
carbenoxolone sodium
1
triterpenoid1982198242.0low010000
chalcone
1
chalconeEC 3.2.1.1 (alpha-amylase) inhibitor2002200222.0low000100
stilbenes
1
stilbene2005200519.0low000100
curcumin
1
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2005200519.0low000100
ranitidine
3
C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic		1990200528.7low102100
nizatidine
1
2004200420.0low100100
zinc protoporphyrin ix
1
2007200717.0low000100
sphingosine
1
sphing-4-eninehuman metabolite;
mouse metabolite		2009200915.0low000100
quercetin
5
7-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger		2003201615.6low000320
bilirubin
1
biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite		201520159.0low000010
dinoprostone
5
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		1981201225.0low020210
alprostadil
1
prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent		2007200717.0low000100
geranylgeraniol
1
geranylgeraniol2005200519.0low000100
rottlerin
1
aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite		2003200321.0low000100
gefarnate
5
organic molecular entity1982200533.0low031100
plaunotol
2
diterpenoid;
primary alcohol		anti-ulcer drug;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
nephroprotective agent;
plant metabolite;
vulnerary		1991201123.0low001010
ornoprostil
1
organic molecular entity2007200717.0low000100
sofalcone
1
aromatic ether;
chalcones;
monocarboxylic acid		anti-ulcer drug;
antibacterial agent;
gastrointestinal drug;
plant metabolite		2002200222.0low000100
menatetrenone
1
menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent		2005200519.0low000100
misoprostol
1
2007200717.0low000100
16,16-dimethylprostaglandin e2
1
cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent		1994199430.0low001000
4-hydroxy-2-nonenal
1
4-hydroxynon-2-enal;
4-hydroxynonenal		2005200519.0low000100
menaquinone 6
1
2005200519.0low000100
sphingosine 1-phosphate
1
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent		2009200915.0low000100
morphine
5
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		201220228.2low000041
enprostil
1
2002200222.0low000100
lysophosphatidic acid
3
1-acyl-sn-glycerol 3-phosphate2005200917.0low000300
aluminum
1
boron group element atom;
elemental aluminium;
metal atom		2007200717.0low000100
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
2
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid2009201114.0low000110
dizocilpine maleate
2
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		2004200420.0low000200
dolichol monophosphate mannose
1
1981198143.0low010000
kb 5492
2
1991199431.5high002000
lactacystin
1
lactam;
S-substituted L-cysteine		2002200222.0low000100
sincalide
1
oligopeptide1990199034.0low001000
knk 437
1
2014201410.0low000010
mocetinostat
8
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		1998200720.8low002600
epoxomicin
1
morpholines;
tripeptide		proteasome inhibitor2002200222.0low000100
alisporivir
1
homodetic cyclic peptideanticoronaviral agent2011201113.0low000010
d-arg-dmt-lys-phe-nh2
1
201720177.0low000010
spergualin
1
N-acyl-amino acid2009200915.0low000100
cytochrome c-t
1
2009200915.0low000100
gastrins
4
1982199137.5low022000
endothelin-1
2
1996201220.0low001010
phosphatidylcholines
3
1,2-diacyl-sn-glycero-3-phosphocholine1987199134.7low012000
calpain
1
2011201113.0low000010
cardiovascular agents
1
201820186.0low000010
glycolipids
1
2009200915.0low000100
piperidines
2
2002201117.5low000110
interleukin-8
2
2002200421.0low100200
transforming growth factor beta
1
202320231.0low000001
bgp 15
1
2011201113.0low000010
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
2
1999200820.5low001100
cyclosporine
1
2011201113.0low000010
silybin
1
2011201113.0low000010
deoxyguanosine
2
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2005201514.0low000110
hypoxanthine
1
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite1991199133.0low001000
3-methyladenine
1
2011201113.0low000010
allopurinol
3
nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger		1993200523.3low001200
noc 18
1
1999199925.0low001000
trypan blue
1
2009200915.0low000100
methylnitronitrosoguanidine
1
nitroso compoundalkylating agent1997199727.0low001000
8-hydroxy-2'-deoxyguanosine
2
guanosinesbiomarker2005201514.0low000110
alcian blue
1
1995199529.0low001000
leptin
2
2010201810.0low000110
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0
1
202320231.0low100001
Abdominal Injuries0
1
202120213.0low000001
Abdominal Pain0
1
2012201212.0low100010
Abnormalities, Drug-Induced0
1
2004200420.0low000100
Absence Seizure0
1
2004200420.0low000100
Acoustic Trauma0
2
2005201215.5low000110
Acute Brain Injuries0
2
201320188.5low000020
Acute Confusional Senile Dementia0
2
201320198.0low100020
Acute Disease0
4
1995200325.2low003100
Acute Edematous Pancreatitis0
1
1995199529.0low001000
Acute Hepatic Failure0
1
2009200915.0low000100
Acute Kidney Failure0
3
2005201414.0low000120
Acute Kidney Injury0
3
2005201414.0low000120
Acute Liver Injury, Drug-Induced0
2
1996200623.0low001100
Adrenal Cancer0
1
2013201311.0low000010
Adverse Drug Event0
1
2012201212.0low000010
Age-Related Osteoporosis0
2
2004200917.5low000200
Aging0
1
2008200816.0low000100
Allergic Encephalomyelitis0
1
2009200915.0low000100
Alloxan Diabetes0
1
2011201113.0low000010
Alveolitis, Fibrosing0
4
200920236.2low000112
Alzheimer Disease0
2
201320198.0low100020
Angiogenesis, Pathologic0
2
200920219.0low000101
Angiospasm, Intracranial0
1
2004200420.0low000100
Anoxemia0
2
200920209.5low000110
Anterior Cerebral Circulation Infarction0
2
2005201016.5low000200
Anterior Choroidal Artery Infarction0
2
2005200618.5low000200
Anterior Circulation Transient Ischemic Attack0
2
2004200619.0low000200
Anterior Horn Cell Disease0
1
2005200519.0low000100
Anterior Optic Neuritis0
1
2009200915.0low000100
Arrhythmia0
1
201820186.0low000010
Arrhythmias, Cardiac0
1
201820186.0low000010
Arteriosclerosis, Coronary0
1
202020204.0low000010
Arthritis, Degenerative0
1
2011201113.0low000010
Arthritis, Rheumatoid0
3
2009201214.0low000210
Astrocytosis0
1
202320231.0low000001
Atrial Fibrillation0
8
2006201912.6low000440
Atrial Remodeling0
1
201920195.0low000010
Atrophy0
2
1997201916.0low101010
Auricular Fibrillation0
8
2006201912.6low000440
Autoimmune Disease0
1
2007200717.0low000100
Autoimmune Diseases0
1
2007200717.0low000100
Autosomal Dominant Juvenile Parkinson Disease0
1
2002200222.0low000100
Bile Duct Obstruction0
1
1992199232.0low001000
Bile Reflux0
1
1999199925.0low001000
Biliary Cirrhosis0
1
202120213.0low000001
Blood Poisoning0
1
2003200321.0low000100
Body Weight0
6
1994201816.8low001320
Bone Diseases, Metabolic0
1
2005200519.0low000100
Bone Loss, Osteoclastic0
1
2005200519.0low000100
Bowel Diseases, Inflammatory0
1
2010201014.0low000100
Brain Edema0
3
2007201810.7low000120
Brain Hemorrhage, Cerebral0
2
2007201811.5low000110
Brain Infarction0
2
2005201016.5low000200
Brain Injuries0
2
201320188.5low000020
Brain Ischemia0
3
2005202110.3low000111
Brain Swelling0
3
2007201810.7low000120
Breast Cancer0
1
2014201410.0low000010
Breast Neoplasms0
1
2014201410.0low000010
Bronchopulmonary Dysplasia0
1
201720177.0low000010
Buckley Syndrome0
1
201620168.0low000010
Cancer of Colon0
3
2009201512.7low000210
Cancer of Liver0
1
1991199133.0low001000
Cancer of Lung0
2
2009201114.0low000110
Cancer of Ovary0
3
2005200917.0low000300
Cancer of Stomach0
3
1998202316.3low001101
Carbon Tetrachloride Poisoning0
1
1996199628.0low001000
Carcinoma, Hepatocellular0
2
1991200128.0low001100
Cardiac Diseases0
2
2006201414.0low000110
Cardiac Failure0
3
201320237.3low100021
Cardiometabolic Syndrome0
1
202320231.0low100001
Cardiomyopathies0
2
200920219.0low000101
Cardiomyopathies, Primary0
2
200920219.0low000101
Cardiovascular Diseases0
1
201820186.0low000010
Cardiovascular Stroke0
3
2008201412.0low000120
Cataract0
1
201720177.0low000010
Cataract, Membranous0
1
201720177.0low000010
Cerebral Hemorrhage0
2
2007201811.5low000110
Cerebral Infarction0
2
2005200618.5low000200
Cerebral Infarction, Middle Cerebral Artery0
3
2005201017.0low000300
Cerebral Ischemia0
3
2005202110.3low000111
Chemical and Drug Induced Liver Injury0
2
1996200623.0low001100
Cholera Infantum0
1
2005200519.0low100100
Cholestasis0
1
1992199232.0low001000
Chronic Disease0
1
2001200123.0low000100
Chronic Hepatitis C0
1
2011201113.0low000010
Chronic Illness0
1
2001200123.0low000100
Chronic Kidney Failure0
1
2008200816.0low000100
Chronic Lung Injury0
2
2009201711.0low000110
Circulatory Collapse0
2
1996200523.5low001100
Cirrhoses, Experimental Liver0
2
1999201815.5low001010
Cirrhosis0
3
2008202310.7low000201
Cirrhosis, Liver0
3
1996201520.3low202010
Cochlear Diseases0
1
2010201014.0low000100
Cochlear Hearing Loss0
1
2005200519.0low000100
Cognition Disorders0
1
201520159.0low000010
Colicky Pain0
1
2012201212.0low100010
Colitis0
3
2005200718.0low000300
Colitis Gravis0
1
201520159.0low000010
Colitis, Ulcerative0
1
201520159.0low000010
Colonic Neoplasms0
3
2009201512.7low000210
Complication, Postoperative0
1
2005200519.0low100100
Congenital Zika Syndrome0
1
202020204.0low000010
Coronary Artery Disease0
1
202020204.0low000010
Cranial Nerve II Diseases0
1
2003200321.0low000100
Cruveilhier-Baumgarten Syndrome0
4
1996200923.8low203100
Curling Ulcer0
3
1981199136.3low012000
Deafness, Transitory0
2
201720177.0low000020
Degenerative Diseases, Central Nervous System0
2
2003200918.0low000200
Depression0
1
201720177.0low000010
Diabetes Mellitus0
1
2014201410.0low000010
Digestive System Diseases0
1
2003200321.0low000100
Digestive System Disorders0
1
2003200321.0low000100
Disease Exacerbation0
2
2007200717.0low000200
Disease Models, Animal0
34
1981202115.2low01415122
Distorted Hearing0
1
201720177.0low000010
Drug Withdrawal Symptoms0
1
2012201212.0low000010
Drug-Related Side Effects and Adverse Reactions0
1
2012201212.0low000010
Duodenal Ulcer0
3
1981199136.3low012000
Dyspepsia0
4
2007201911.5low400130
Encephalopathy, Toxic0
1
2013201311.0low000010
Esophageal Reflux0
1
2012201212.0low100010
Exertional Heat Illness0
2
2000201118.5low001010
Experimental Lung Inflammation0
1
202320231.0low000001
Experimental Radiation Injuries0
2
201620177.5low000020
Failure to Thrive0
1
201720177.0low000010
Fatty Liver, Nonalcoholic0
1
202120213.0low000001
Fever0
3
2007200916.3low000300
Fibrosis0
3
2008202310.7low000201
Fibrosis, Radiation0
1
201620168.0low000010
Gastric Diseases0
5
1981200626.0low112200
Gastric Stasis0
1
2012201212.0low100010
Gastric Ulcer0
34
1981201227.8low49131110
Gastritis0
7
1996201221.0low403310
Gastritis, Atrophic0
1
2007200717.0low000100
Gastroduodenal Ulcer0
8
1983201426.1low231310
Gastroesophageal Reflux0
1
2012201212.0low100010
Gastrointestinal Hemorrhage0
3
1996200524.0low102100
Gastroparesis0
1
2012201212.0low100010
Glaucoma0
2
2003200321.0low000200
Glucose Intolerance0
2
2011201411.5low000020
Granulocytic Leukemia0
1
1993199331.0low001000
Hearing Loss0
2
201720177.0low000020
Hearing Loss, Noise-Induced0
2
2005201215.5low000110
Hearing Loss, Sensorineural0
1
2005200519.0low000100
Heart Disease, Ischemic0
5
2001201217.8low000410
Heart Diseases0
2
2006201414.0low000110
Heart Failure0
3
201320237.3low100021
Heat Stroke0
1
2010201014.0low000100
Heatstroke0
1
2010201014.0low000100
Helicobacter Infections0
8
1998200722.4low404400
Hematochezia0
3
1996200524.0low102100
Hematoma0
1
201820186.0low000010
Hemorrhage, Subarachnoid0
1
2004200420.0low000100
Hepatitis C, Chronic0
1
2011201113.0low000010
Hepatocellular Carcinoma0
2
1991200128.0low001100
Hyperglycemia0
1
2011201113.0low000010
Hyperglycemia, Postprandial0
1
2011201113.0low000010
Hyperoxia0
1
201720177.0low000010
Hypertension, Portal0
4
1996200923.8low203100
Hypoxia0
2
200920209.5low000110
Idiopathic Parkinson Disease0
1
201820186.0low000010
Impaired Glucose Tolerance0
2
2011201411.5low000020
Inadequate Sleep0
1
2006200618.0low000100
Indigestion0
4
2007201911.5low400130
Infarction, Middle Cerebral Artery0
3
2005201017.0low000300
Infections, Helicobacter0
8
1998200722.4low404400
Infections, Orthomyxoviridae0
1
2003200321.0low000100
Inflammation0
5
2005202313.0low000311
Inflammatory Bowel Diseases0
1
2010201014.0low000100
Injuries, Radiation0
1
201620168.0low000010
Injuries, Spinal Cord0
1
2005200519.0low000100
Injury, Ischemia-Reperfusion0
13
1995202315.0low004252
Injury, Myocardial Reperfusion0
6
2001201416.3low000420
Innate Inflammatory Response0
5
2005202313.0low000311
Insulin Resistance0
4
2005201812.0low000220
Insulin Sensitivity0
4
2005201812.0low000220
Intestinal Diseases0
3
2010201511.0low100120
Intraocular Pressure0
1
2003200321.0low000100
Invasiveness, Neoplasm0
2
2005200917.0low000200
Ischemia0
5
1995201120.4low002210
Ischemic Attack, Transient0
2
2004200619.0low000200
Job Syndrome0
1
201620168.0low000010
Keratitis0
1
2013201311.0low000010
Kidney Failure, Chronic0
1
2008200816.0low000100
Left Ventricular Dysfunction0
1
202320231.0low100001
Leukemia, Myeloid0
1
1993199331.0low001000
Liver Cirrhosis0
3
1996201520.3low202010
Liver Cirrhosis, Biliary0
1
202120213.0low000001
Liver Diseases0
1
1991199133.0low001000
Liver Dysfunction0
1
1991199133.0low001000
Liver Failure, Acute0
1
2009200915.0low000100
Liver Neoplasms0
1
1991199133.0low001000
Low Bone Density0
1
2005200519.0low000100
Lung Neoplasms0
2
2009201114.0low000110
Lymphoma of Mucosa-Associated Lymphoid Tissue0
1
1998199826.0low001000
Lymphoma, B-Cell, Marginal Zone0
1
1998199826.0low001000
Malignant Melanoma0
1
201620168.0low000010
Melanoma0
1
201620168.0low000010
Metabolic Syndrome0
1
202320231.0low100001
Metastase0
2
2009200915.0low000200
MODS0
1
2010201014.0low000100
Morphine Abuse0
2
201220189.0low000020
Morphine Dependence0
2
201220189.0low000020
Motor Neuron Disease0
1
2005200519.0low000100
Multiple Organ Failure0
1
2010201014.0low000100
Muscle Contraction0
2
2003201913.0low000110
Myocardial Infarction0
3
2008201412.0low000120
Myocardial Ischemia0
5
2001201217.8low000410
Necrosis0
3
2001200620.0low000300
Neoplasm Metastasis0
2
2009200915.0low000200
Nerve Degeneration0
1
2005200519.0low000100
Neuroblastoma0
1
201520159.0low000010
Neurodegenerative Diseases0
2
2003200918.0low000200
Non-alcoholic Fatty Liver Disease0
1
202120213.0low000001
Obesity0
1
202320231.0low100001
Optic Nerve Diseases0
1
2003200321.0low000100
Optic Neuritis0
1
2009200915.0low000100
Orthomyxoviridae Infections0
1
2003200321.0low000100
Osteoarthritis0
1
2011201113.0low000010
Osteogenic Sarcoma0
1
202120213.0low000001
Osteoporosis0
2
2004200917.5low000200
Osteosarcoma0
1
202120213.0low000001
Ovarian Neoplasms0
3
2005200917.0low000300
Pancreatitis0
1
1995199529.0low001000
Parkinson Disease0
1
201820186.0low000010
Parkinsonian Disorders0
1
2002200222.0low000100
Peptic Ulcer0
8
1983201426.1low231310
Peritonitis0
1
2011201113.0low000010
Pheochromocytoma0
1
2013201311.0low000010
Pheochromocytoma, Extra-Adrenal0
1
2013201311.0low000010
Pigmentary Retinopathy0
1
201620168.0low000010
Pneumonia0
1
202320231.0low000001
Poisoning0
1
2005200519.0low000100
Postoperative Complications0
1
2005200519.0low100100
Pregnancy0
1
2004200420.0low000100
Presbycusis0
1
2008200816.0low000100
Primary Peritonitis0
1
2011201113.0low000010
Pulmonary Fibrosis0
4
200920236.2low000112
Pyrexia0
3
2007200916.3low000300
Radiation Pneumonitis0
1
201620168.0low000010
Recrudescence0
3
1988201822.7low111010
Reperfusion Injury0
13
1995202315.0low004252
Retinal Detachment0
1
2011201113.0low000010
Retinal Diseases0
3
200520239.3low000111
Retinal Pigment Epithelial Detachment0
1
2011201113.0low000010
Retinitis Pigmentosa0
1
201620168.0low000010
Rheumatic Diseases0
1
201520159.0low100010
Rheumatism0
1
201520159.0low100010
Rheumatoid Arthritis0
3
2009201214.0low000210
Seizures0
1
2004200420.0low000100
Sensitivity and Specificity0
1
2007200717.0low000100
Sepsis0
1
2003200321.0low000100
Shock0
2
1996200523.5low001100
Spinal Cord Injuries0
1
2005200519.0low000100
Stomach Neoplasms0
3
1998202316.3low001101
Stomach Ulcer0
34
1981201227.8low49131110
Subarachnoid Hemorrhage0
1
2004200420.0low000100
Substance Withdrawal Syndrome0
1
2012201212.0low000010
Tachyarrhythmia0
1
2011201113.0low000010
Tachycardia0
1
2011201113.0low000010
Ulcer0
4
2005202311.8low200211
Uveitis0
1
2007200717.0low000100
Vasospasm, Intracranial0
1
2004200420.0low000100
Ventricular Dysfunction, Left0
1
202320231.0low100001
Weight Loss0
1
1994199430.0low001000
Weight Reduction0
1
1994199430.0low001000
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (14)

ArticleYear
Mitochondria-targeting nanomedicine: An effective and potent strategy against aminoglycosides-induced ototoxicity.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jan-01, Volume: 126		2019
Geranylgeranylacetone Ameliorates Intestinal Radiation Toxicity by Preventing Endothelial Cell Dysfunction.
International journal of molecular sciences, , Oct-07, Volume: 18, Issue:10		2017
Evaluation of geranylgeranylacetone against cisplatin-induced ototoxicity by auditory brainstem response, heat shock proteins and oxidative levels in guinea pigs.
Neurotoxicology and teratology, , Volume: 61		2017
Geranylgeranylacetone blocks doxorubicin-induced cardiac toxicity and reduces cancer cell growth and invasion through RHO pathway inhibition.
Molecular cancer therapeutics, , Volume: 13, Issue:7		2014
Protective effect of geranylgeranylacetone against methamphetamine-induced neurotoxicity in rat pheochromocytoma cells.
Pharmacology, , Volume: 92, Issue:3-4		2013
[Side effects of non-steroidal anti-inflammatory drugs on gastric mucosa and preventive effects of teprenone].
Zhonghua yi xue za zhi, , Apr-28, Volume: 89, Issue:16		2009
Protective effect of geranylgeranylacetone on cisplatin ototoxicity.
Chemotherapy, , Volume: 55, Issue:1		2009
Effect of geranylgeranylacetone on gentamycin ototoxicity in rat cochlea culture.
Auris, nasus, larynx, , Volume: 34, Issue:1		2007
Geranylgeranylacetone protects against acetaminophen-induced hepatotoxicity by inducing heat shock protein 70.
Toxicology, , Feb-15, Volume: 219, Issue:1-3		2006
Oral administration of geranylgeranylacetone plus local somatothermal stimulation: a simple, effective, safe and operable preconditioning combination for conferring tolerance against ischemia-reperfusion injury in rat livers.
World journal of gastroenterology, , Sep-28, Volume: 11, Issue:36		2005
[Possible candidates for the compound which is expected to attenuate dioxin toxicity].
Fukuoka igaku zasshi = Hukuoka acta medica, , Volume: 96, Issue:5		2005
Reduction of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice using an antiulcer drug, geranylgeranylacetone.
Biological & pharmaceutical bulletin, , Volume: 27, Issue:9		2004
Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells.
Neuroscience letters, , Mar-15, Volume: 321, Issue:1-2		2002
Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes.
Biochemical and biophysical research communications, , Sep-07, Volume: 275, Issue:3		2000

Long-term Use (2)

ArticleYear
Geranylgeranylacetone protects against morphine-induced hepatic and renal damage in mice.
Molecular medicine reports, , Volume: 7, Issue:2		2013
[Side effects of non-steroidal anti-inflammatory drugs on gastric mucosa and preventive effects of teprenone].
Zhonghua yi xue za zhi, , Apr-28, Volume: 89, Issue:16		2009

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46		2019

Dosage (4)

ArticleYear
Protective effect of geranylgeranylacetone against methamphetamine-induced neurotoxicity in rat pheochromocytoma cells.
Pharmacology, , Volume: 92, Issue:3-4		2013
Serum and stomach tissue levels of geranylgeranylacetone in patients.
International journal of clinical pharmacology, therapy, and toxicology, , Volume: 21, Issue:6		1983
Incorporation of radioactivity into amino acids and fatty acids after administration of 14C-geranylgeranylacetone to rats.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 17, Issue:4		1987
Geranyl-geranyl acetone: a novel stimulant of secretin release in the dog.
Pancreas, , Volume: 5, Issue:5		1990

Interactions (1)

ArticleYear
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Digestive diseases and sciences, , Volume: 43, Issue:9 Suppl		1998